This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allergan Authorizes New $2B Share Buyback Plan, Stock Up
by Zacks Equity Research
Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.
Teva/Nuvelution to Speed Up Development of Austedo in US
by Zacks Equity Research
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.
Teva's Leukemia Drug sNDA Granted Priority Review by the FDA
by Zacks Equity Research
Teva Pharmaceutical's (TEVA) sNDA for label expansion of Trisenox as first-line treatment of acute promyelocytic leukemia has been accepted by the FDA under priority review.
Company News For Sep 13, 2017
by Zacks Equity Research
Companies in the news are: TEVA,WDC,AMZN,LMNR
Teva's New CEO Brings No Relief: Generic Drugmakers to Dump
by Zacks Equity Research
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
Company News For Sep 12, 2017
by Zacks Equity Research
Companies in the news are: TEVA,BMY,EFX,FB
Cooper Companies Buys Teva's PARAGARD Intrauterine Platform
by Zacks Equity Research
Cooper Companies (COO) latest development is expected to fortify its foothold in the contraceptive device market. Margins are likely to improve within one year of the deal closure.
Why Did Teva Pharmaceuticals Stock Soar Today?
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA) opened more than 15% higher on Monday after the struggling drugmaker picked H. Lundbeck (HLUYY) chief Kare Schultz to fill its long-vacant CEO role.
Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?
by Zacks Equity Research
Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.
Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study
by Zacks Equity Research
Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.
Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia
by Zacks Equity Research
Teva Pharmaceutical (TEVA) announced that the FDA has approved the label expansion of Austedo to include tardive dyskinesia in adults. Shares are up since announcement.
Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.
SolarEdge (SEDG) and Teva (TEVA) are Blowouts!
by Brian Bolan
One stock is being blown off the books and one had a blow out earnings report.
Teva Plunges to 10-Year Low, Credit Rating in Jeopardy
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA), a favorite for investors chasing large dividend yields, fell more than 4.4%--and hit a 10-year intraday low--on Wednesday.
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
by Zacks Equity Research
VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.
Generic Drug Stocks Take a Hit: Here's Why
by Arpita Dutt
As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.
Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps
by Zacks Equity Research
Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.
Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down
by Zacks Equity Research
Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.
Teva (TEVA) Q2 Earnings and Sales Miss, Shares Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) second quarter earnings and revenue missed estimates. The company has also lowered its earnings and revenue guidance for 2017.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.
Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?
by Zacks Equity Research
While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness.
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
by Zacks Equity Research
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).